The collaboration combines Lunit’s AI expertise with Agilent’s diagnostic leadership to improve biomarker testing and enhance precision medicine capabilities.
Lunit and Agilent Technologies announced a nonexclusive collaboration to develop artificial intelligence (AI)-based companion diagnostic solutions that combine AI with tissue-based diagnostic expertise to advance precision medicine capabilities.
The partnership will leverage Lunit’s AI algorithms with Agilent’s assays to evaluate biomarkers critical for pharmaceutical therapy development. The collaboration aims to enhance accuracy in diagnosis and measurement of therapeutic efficacy while supporting pharmaceutical companies in companion diagnostic product development.
“Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation,” says Brandon Suh, CEO of Lunit, in a release. “By combining Agilent’s global leadership in tissue-based diagnostics with Lunit’s proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence – ultimately ensuring patients receive the right treatment at the right time.”
The collaboration will initially focus on co-developing AI-powered assays for research and clinical trials. The joint solutions are designed to improve precision and accuracy of biomarker testing, potentially providing patients with more tailored treatment options.
Addressing Manual Interpretation Challenges
The partnership addresses current limitations in biomarker testing, which relies heavily on manual interpretation. The companies plan to create advanced solutions that meet demand for novel and complex biomarker assays in drug development.
“Agilent is committed to bringing cutting-edge diagnostic solutions to our pharmaceutical partners and ultimately to patients, and this collaboration with Lunit further strengthens our ability to offer the most advanced companion diagnostic solutions available today,” says Nina Green, vice president and general manager of Agilent’s Clinical Diagnostics Division, in a release. “Through this collaboration with Lunit, we aim to deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide.”
ID 32581342 © Agsandrew | Dreamstime.com
